Lutathera and ASTX727 in Neuroendocrine Tumours

NCT05178693 | Recruiting Phase 1 DMC

• 2 other identifiers: RS - IC0321HH6544
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use \[68Ga\]-DOTA-TATE PET to image epigenetic modification of the receptor locus.

Conditions

Neuroendocrine Tumors

Outcome Measures

Primary Outcomes (1)

• To determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using [68Ga]-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera

  This outcome will be assessed using a specific PET scan

  Through study completion, an average of 1 year

Secondary Outcomes (4)

• To assess tolerability of combination therapy

  Through study completion, an average of 1 year

• To assess response to treatment using conventional imaging

  Through study completion, an average of 1 year

• To assess patients quality of life during treatment

  Through study completion, an average of 1 year

• To assess progression free survival

  Through study completion, an average of 1 year

Study Arms (1)

Treatment

EXPERIMENTAL

Drug: ASTX727; Radiation: Lutathera

Interventions

ASTX727 DRUG

Cedazuridine 100mg + 35mg decitabine

Treatment

Lutathera RADIATION

Peptide receptor radionuclide therapy (PRRT)

Also known as: lutetium Lu 177 dotatate

Treatment

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be willing and able to provide written informed consent for the trial.
• Be aged 18 or over at the day of signing consent
• Histologic or cytologic confirmed diagnosis of neuroendocrine tumour
• Have archival tissue block available or willing to have fresh tissue biopsy if blocks not available
• Have disease that can be readily biopsied by ultrasound guidance (n=5)
• Ki67 \< 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months)
• Progression or intolerance to first line therapy including somatostatin analogues
• ECOG Performance status 0 - 2
• No tumoural uptake on \[68Ga\]-DOTA-TATE or uptake less than background liver
• Measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
• Adequate organ function as outlined in the protocol
• Women of childbearing potential must be willing to use a highly effective method of contraception as outlined in the protocol for the course of the study through 6 months after the last dose of Investigational Medicinal Product (IMP).
• Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects
• Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

You may not qualify if:

• Previous treatment with either study medication and/or known hypersensitivity to the study medication
• Serious concurrent medical illness, including serious active infection
• History of organ transplant
• Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.
• Has a known history of active Bacillus Tuberculosis (TB).
• Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
• Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage
• Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP.
• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP.
• Has received a live vaccine within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
• Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
• Other clinically significant co-morbidities that could compromise the subject's participating in the study

Sponsors & Collaborators

• Imperial College London: lead
• Advanced Accelerator Applications: collaborator

Study Sites (1)

Hammersmith Hospital

London, London, City of, W12 0HS, United Kingdom

RECRUITING

Related Publications (1)

• Murphy R, Chander G, Martinez M, Ward C, Khan SR, Naik M, Barwick T, Aboagye E, Sharma R. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. BMJ Open. 2023 Oct 24;13(10):e075221. doi: 10.1136/bmjopen-2023-075221.

  PMID: 37879695 DERIVED

MeSH Terms

Conditions

Neuroendocrine Tumors

Interventions

decitabine and cedazuridine drug combination; lutetium Lu 177 dotatate

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Study Officials

• Rohini Sharma, Professor

  Imperial College London

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rohini Sharma, Professor

CONTACT

02083833170; rohini.sharma2@nhs.net

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 3, 2021
• First Posted: January 5, 2022
• Study Start: April 25, 2022
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): February 28, 2029
• Last Updated: November 24, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)